ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic neoplasms (MDS) are a group of highly heterogeneous myeloid malignancies characterized by cytopenia, dysplasia, and a high risk of leukemic transformation. Next-generation sequencing (NGS) technology enables efficient detection of gene mutations and has been incorporated into the diagnostic classification, prognostic assessment, and treatment decision-making systems for MDS. To further standardize the clinical application of NGS technology in MDS, Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association have developed this expert consensus by integrating the latest advances in MDS diagnosis and treatment, relevant domestic and international guidelines/consensus recommendations, and expert opinions from China. The aim is to promote the rational use of NGS in the diagnosis and treatment of MDS in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.